We expect the ulcerative colitis (UC) market to grow steadily over the next decade, primarily driven by the increasing use of non-tumor necrosis factor (TNF) biologics (e.g., Takeda’s Entyvio, Janssen’s Stelara) earlier in the treatment algorithm. Additionally, the availability of Pfizer’s Xeljanz / Xeljanz XR has expanded physicians’ treatment armamentarium and intensified market competition. Furthermore, the recent approvals of BMS’s Zeposia, Gilead / Galapagos’s Jyseleca, and AbbVie’s Rinvoq, and the expected launch of several emerging therapies with novel mechanisms of action (MOAs) (e.g., Skyrizi, Tremfya, mirikizumab, ABX464) will drive market growth over the next decade. In addition to these factors, the continued generics erosion of conventional agents and the entry of and increased physician comfort with less expensive biosimilars will constrain the UC market and create hurdles that emerging therapies will need to overcome to secure uptake.
QUESTIONS ANSWERED
CONTENT HIGHLIGHTS
Geographies: United States, EU5, Japan.
Primary research: 28 country-specific interviews with thought-leading gastroenterologists; supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalence of UC by country, segmented by disease activity.
Forecast: Ten-year, annualized, drug-level sales and patient share of key UC therapies through 2031, segmented by brands / generics / biosimilars, and acute and maintenance settings.
Emerging therapies: Phase III/PR: ~7 drugs; coverage of select early-phase products.
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.